New weight loss drug begins first human testing
NCT ID NCT07160400
Summary
This early-stage study is testing a new drug called IBI3032 for weight management. Researchers will first give single doses to healthy volunteers to check safety, then give multiple doses to people with overweight or obesity over four weeks. The main goal is to see how safe the drug is and how the body processes it, not to measure weight loss effectiveness at this stage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PART A: HEALTHY PART B: OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital affiliated to Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.